Cancer Immunotherapy Market Size, Sales, Growth Insights and Competitive Outlook To 2027
Cancer Immunotherapy Market Highlights
Global
cancer immunotherapy market is expecting growth at a very
high rate in the coming future. This is due to the increasing number of
patients suffering from different types of cancer. Globally approximately 100
types of different types of cancer have been registered. And in terms of
treatment, limited number of treatments are available in the market. Cancer
immunotherapy is expecting to make a huge development in coming future due to
its various advantages. Immunotherapy is more effective than other available
therapies and have lesser side effects. Increasing cancer population across the
globe is a direct consequence of the lowering health standards i.e. increasing
smoking and alcohol intake in millennial population has led to an increase in
the number of lung and liver cancers. Which has provided a fuel for the
development of the market. Long time for approval, high cost of treatment and
many adverse effects may hinder the market growth.
In
2016, the global cancer immunotherapy market was valued at USD 36 billion.
Which is expected to grow at a CAGR of 14.8% within a forecasted period from
2017-2023. The global immunotherapy market is expected to reach USD 101.6
billion by the end of 2023.
Regional Analysis
On
regional basis, Global immunotherapy market is analysed for major regions of
the world i.e. North America, Europe, Asia Pacific and the Middle East and
Africa.
North
America is the major contributor in the market because of huge technological
advances and affordability of treatment. Beside this, a well-established
healthcare sector and ample amount of expenditure in healthcare has attracted
many of the manufacturers to this region.
Europe
holds the second largest share of the global cancer immunotherapy market as
result of increasing focus of various government agencies on the treatment of
disease like cancer.
Improvement
in healthcare infrastructure, rise in healthcare expenditure and increase in
per capita income in Asia Pacific region has made this region as the fastest
growing region.
The Middle East and Africa
holds a relatively lower market share in comparison to others.
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/567
Segmentation
The
global cancer immunotherapy market is segmented on the basis of therapy types,
by application, by end user.
On the
basis of type, it is segmented into monoclonal antibodies, adoptive cell
transfer, cytokines, treatment vaccines, bacillus calmette-guérin, and others.
Monoclonal antibodies further segmented into naked monoclonal antibodies,
conjugated monoclonal antibodies, and bispecific monoclonal antibodies.
Cytokines are further segmented into Interferon, Interleukins. On the basis of
application, it is segmented into liver cancer, childhood cancer, colorectal
cancer, stomach cancer, lung cancer and others. On the basis of end user, it is
segmented into hospitals, clinics, and others.
Key Players
Some of
key the players in the market are F. Hoffmann-La Roche AG, Merck & Co.,
Inc., Novartis International AG, GlaxoSmithKline Plc., Amgen Inc.,
Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle
Genetics, Inc., Spectrum Pharmaceuticals, Inc.
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/global-cancer-immunotherapy-market-567
About
Market Research Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
& Consulting Services. MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment